Kyushu University researchers identify LASSS compound to boost muscle repair

Researchers at Kyushu University have identified a compound capable of enhancing skeletal muscle repair by strengthening a critical protein signaling pathway, a discovery that could offer a new approach to managing muscle degradation associated with aging. The findings, published July 24, 2026, center on a molecule known as lipoic acid trisulfide (LASSS), which appears to protect and potentially "supercharge" hepatocyte growth factor (HGF).

HGF is a protein essential for triggering muscle tissue regeneration. Under normal circumstances, HGF remains inactive until an injury occurs, at which point it binds to c met receptors on satellite cells — the stem cells responsible for muscle maintenance. However, aging often compromises this process through a chemical modification known as nitration, which renders the protein unable to fit its receptor, much like a rusted key in a lock. Professor Ryuichi Tatsumi, who led the research, suggests that LASSS acts beyond simple antioxidant functions. By mixing HGF with LASSS, the researchers observed a structural change that allowed the protein to bind more effectively to its receptor, resisting the functional loss caused by nitration.

Related imagery

The discovery arrives amid a broader, intensifying debate regarding the clinical use of peptide-based therapies. While the Kyushu University findings remain in the experimental stage — having shown promise in mouse models of muscle atrophy, the medical and regulatory communities are currently grappling with the proliferation of unauthorized, compounded peptides such as BPC-157, TB-500, and MOTS-C.

Regulatory Divergence

The landscape for muscle-related interventions remains highly fragmented. While legitimate research into compounds like LASSS seeks to establish verifiable biological pathways, many patients are currently accessing unregulated peptides. A recent investigation by Cbc News highlighted a regulatory gap that allows doctors to prescribe compounded peptides as natural health products, even when they lack rigorous clinical approval. Experts like Timothy Caulfield of the University of Alberta have characterized this as a trend that leverages wellness marketing despite a "lack of established human dosing protocols."

This conflict is mirrored at the federal level in the United States. As of July 24, 2026, independent FDA advisers have voted to recommend the reclassification of several peptides to allow for broader availability through compounding pharmacies. This move has drawn support from various "looksmaxxing" and longevity communities, as well as firms that stand to benefit from the market shift. However, FDA scientists have cautioned that these recommendations contradict their own assessments, which cite a lack of well-run safety and efficacy trials.

Clinical Context and Future Research

The potential for these compounds to address conditions such as age-related muscle wasting remains a central goal of ongoing investigation, but practitioners warn that findings from animal models do not always translate to humans. Patricia Brubaker, a professor emeritus at the University of Toronto, emphasized that true medical progress requires rigorous clinical trials to ensure safety and effective dosing at each stage of development.

For those navigating muscle health and aging, experts recommend a complex approach:

• Nutrition: An anti-inflammatory diet rich in protein (aiming for 30–40 grams per meal) and fiber is often recommended to support metabolic health and lean muscle mass.
• Supplements: Some menopause experts note potential benefits from creatine and magnesium, though they stress the importance of third-party testing to ensure ingredient accuracy.
• Clinical Guidance: As hormonal fluctuations and aging processes often overlap, individuals are encouraged to seek guidance from specialized clinicians, such as those associated with the Menopause Society, rather than relying on unproven self-administered substances.

What happens next for the Kyushu University team involves transitioning from isolated protein and animal experiments to longitudinal studies on aging subjects to determine if LASSS is both safe and effective in living organisms. Simultaneously, the FDA is expected to weigh the advisory committee's recommendations against the concerns of its own staff, a decision that will dictate the legal availability of popular peptides in the coming months. As these paths develop, the distinction between established, evidence-based regenerative research and the current "gray market" for wellness-focused peptides will likely remain a critical focal point for health regulators.